Search company, investor...
Enzymit company logo

Enzymit

enzymit.com

Founded Year

2020

Stage

Seed VC | Alive

Total Raised

$5.09M

Last Raised

$5M | 1 yr ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+130 points in the past 30 days

About Enzymit

Enzymit creates the knowledge and tools to design and build novel biomolecular components. The company offers a platform technology using computational algorithms to build molecular machines to solve humanity's challenges. The company was founded in 2020 and is based in Ness-Ziona, Israel.

Headquarters Location

Pinhas Sapir Street 3 Daren labs, Ness Ziona - Science Park

Ness Ziona,

Israel

972-50-422-2987

Missing: Enzymit's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Enzymit's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Enzymit News

Startup Develops New Insulin To Accelerate Cultivated Meat Growth

May 21, 2023

Enzymit will help Aleph Farms spur the development of its cultivated meat. (Courtesy of Aleph Farms) An Israeli startup is shortening the time it takes to develop large amounts of cultivated meat, by producing new kinds of insulin to spur the growth process. Enzymit creates the form of insulin normally mass produced from the pig or cow pancreas, which is cheaper and helps grow animal cells more quickly. The startup is partnering with Rehovot-based food technology company Aleph Farms to “dramatically” reduce the production time and costs of cultivated meat, which normally takes up to eight weeks to produce. The companies say that the partnership has the potential to increase the production of other cultivated meats such as chicken, lamb and pork. Enzymit uses computer algorithms to create enzymes (the proteins that create a chemical reaction) and inputs desired traits. The algorithm then generates a new sequence that – when inserted into bacteria – turns them into insulin-producing “factories.” “Developing more suitable processing aids for the production of cultivated meat is imperative for driving economies of scale and taking cultivated meat mainstream,” said Dr. Neta Lavon, CTO of Aleph Farms. “This innovation, combining Enzymit’s outstanding protein design and experimental capabilities with our team’s expertise in cellular agriculture, is helping to build the foundations for our sector to achieve cost-efficiency and long-term impact.” Dr. Gideon Lapidoth, CEO of Enzymit, said: “Creating highly stable and more active insulin substituents can markedly reduce the cost of growth media and increase efficiency in producing cultivated meat at scale.” Subscribe to NoCamels weekly newsletter and get our top stories

Enzymit Frequently Asked Questions (FAQ)

  • When was Enzymit founded?

    Enzymit was founded in 2020.

  • Where is Enzymit's headquarters?

    Enzymit's headquarters is located at Pinhas Sapir Street 3, Ness Ziona.

  • What is Enzymit's latest funding round?

    Enzymit's latest funding round is Seed VC.

  • How much did Enzymit raise?

    Enzymit raised a total of $5.09M.

  • Who are the investors of Enzymit?

    Investors of Enzymit include First Star Ventures, Sapir Venture Partners, StartLife and MassChallenge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.